Kienbaum, Peter
Schaefer, Maximilian S.
Weibel, Stephanie
Schlesinger, Tobias
Meybohm, Patrick
Eberhart, Leopold H.
Kranke, Peter
Article History
Accepted: 1 September 2021
First Online: 1 October 2021
Einhaltung ethischer Richtlinien
:
: P. Kienbaum: Consulting fees: Baxter Germany, TEVAR ratiopharm GmbH; Payment for lectures: Baxter Germany, Orion Pharma Germany, Participation on a Data Safety Monitoring Board or Advisory Board: DAMB (HandiCAP-Tial Münster), AdBoard (TEVAR ratiopharm). M.S. Schaefer: Grants or contracts from any entity: Has received a grant for investigator-initiated studies from Merck & Co. Other financial or non-financial interests: co-author of the Cochrane Review (Weibel et al. 2020). T. Schlesinger: Other financial or non-financial interests: co-author of the Cochrane Review (Weibel et al. 2020). L.H. Eberhart: Consulting fees: Fresenius Kabi GmbH, TEVA ratiopharm GmbH. P. Kranke: Grants or contracts from any entity: NHS Funding (Cochrane Review, (Weibel et al. 2020)); Consulting fees: TEVA ratiopharm GmbH, Fresenius Kabi, CSL Behring, Vifor; Support for attending meetings: Department Resources (PONV Consensus Panel in Las Vegas); Participation on a Data Safety Monitoring Board or Advisory Board: Vifor; Leadership or fiduciary role in other board, society, committee or advocacy group: Guideline Committee of the ESAIC, WFSFA Obstetric Committee, DGAI. S. Weibel und P. Meybohm geben an, dass kein Interessenkonflikt besteht.
: Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.